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leukaemia16) were not predicted by animal studies
using similar doses of vector.
One set of questions on toxicology related to gene
transfer arises because most studies in humans—as
with many other trials of hazardous agents—enrol par-
ticipants with advanced illness. Such participants are
likely to misinterpret the purpose of the trial as provid-
ing therapy rather than producing generalisable
knowledge.17 Enrolment in studies on the safety of
gene transfer is therefore susceptible to being based on
“misinformed” consent. Also, participants who per-
ceive a trial as providing therapy may be less willing to
comply with intrusive procedures (for example, long
term follow up and autopsy) that are aimed at testing
safety. By policing consent procedures for language
that promotes misconceptions about therapy, investi-
gators may encourage participants to cooperate with a
trial’s toxicological aspects.18
Premarketing studies of drugs often have insuffi-
cient power to expose rare adverse events19; the collec-
tion of toxicity data is further hampered because gene
transfer trials generally enrol participants with severe
illness. For instance, attributing causes for adverse
events is confounded by underlying medical conditions.
Moreover, such populations are unlikely to survive and
experience theoretically predicted latent adverse events.
Therefore, many risks will only be characterised once
gene transfer extends to populations with less severe
medical conditions; patients and the public (rather than
trial participants) will likely bear many of the risks
involved in characterising latent toxicity.
Owing to the uncertainties and inexperience
surrounding risks from gene transfer, systems may
need to be established for postmarketing surveillance
(for example, registries) and the long term follow up of
trial participants. In the United States, such long term
follow up is not mandatory, and anecdotal evidence
indicates that it is not widely practised.18 In contrast, the
United Kingdom20 and Australia (www7.health.gov.au/
nhmrc/research/gtrap.htm) track the medical records
of recipients of gene transfer. Follow up and post-
marketing surveillance are potentially costly, can medi-
calise people’s lives, and infringe on their privacy.
Nevertheless, spontaneous reporting of adverse events
is unreliable for detecting latent adverse events,19 and
more active measures may be necessary to protect the
public, and patients and their descendants, should
gene transfer expand to milder medical conditions.
Although recent trials confirm the feasibility of
gene therapy, they also highlight that its risks are
poorly understood. The task for researchers in gene
transfer will be to characterise these risks while attend-
ing to the complex ethical challenges of conducting
gene transfer studies in humans.
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Corrections and clarifications
The next small step
The author of this article in our Christmas issue,
Kevin Fong, has notified us that his email address
is missing its first full stop (BMJ 2004;329:1441-4,
18-25 Dec). His correct address is k.fong@ucl.ac.uk.
Monitoring global health: time for new solutions
The authors of this Education and Debate article
(who argued that a new global health monitoring
organisation is needed to replace the World Health
Organization) would like to clarify for readers that
they have all had recent links with WHO
(BMJ 2004;329:1096-100, 6 Nov). Christopher J L
Murray worked for WHO until 15 September 2003,
Alan D Lopez worked for the organisation until
1 January 2002, and Suwit Wibulpolprasert has
served on a number of advisory committees to WHO.
If the honey doesn’t get you, the bees will
A lapse in concentration by Harvey Marcovitch, the
author of the summaries on the BMJ Family
Highlights page, led to the inadvertent omission of
the word haemorrhagic in this summary on the
BMJ Family Highlights page (BMJ 2004;329:1368,
11 Dec). The third sentence should have read:
“Computed tomography of the head and magnetic
resonance imaging of the brain showed a large
right temporo-occipital haemorrhagic infarct.”
Cadavers as teachers: the dissecting room experience in
Thailand
In this article by Andreas Winkelmann and Fritz H
Güldner in our Christmas issue, we forgot to carry
out the authors’ wishes that we acknowledge
Professor G H Schumacher from Rostock,
Germany, as the provider of the photograph
(BMJ 2004;329:1455-7, 18-25 Dec).
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